Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | , , , , , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1867021538735161344 |
|---|---|
| author | Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca |
| author_facet | Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca |
| collection | Wiley Open Access |
| contents | Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca Australasian Journal of Dermatology AbstractPalmoplantar (PP) psoriasis is considered one of the most hard‐to‐treat areas with important impact on patients' quality of life, and few data are available about the efficacy of dimethylfumarate (DMF) on these areas. In our noninterventional multicentre retrospective cohort study of patients with PP psoriasis treated with DMF, effectiveness was evaluated as mean pp Psoriasis Area and Severity Index (ppPASI) reduction and as proportion of patients that reach ppPASI 75 at 4, 12, 24 and 48 weeks. The reduction in ppPASI was 23.5% at w4, 49.7% at w12, 69.1% at w24 and 81.1% at w48. pp Investigator's Global Assessment (ppIGA) 0/1 was reached by 5 patients (10.64%) at w4, 10 patients (23.8%) at w12, 11 patients (40.7%) at w24 and 12 patients (60%) at w48 confirming that DMF could represent an effective therapy in patients affected by PP psoriasis. Overall, the treatment was well tolerated although only 24 patients made it to 24 weeks of therapy and 28 patients completed the observation period at 48 weeks. None of the patients reported adverse events requiring discontinuation of the drug. However, this discontinuation rate is in line with clinical trials and real‐world evidence. 10.1111/ajd.14213 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ajd.14213 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ajd_14213 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca Australasian Journal of Dermatology Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study Caldarola Giacomo Trovato Emanuele Burlando Martina Capalbo Eugenio Diotallevi Federico Lora Viviana Pinto Lorenzo Maria Gaeta Shumak Ruslana Fastame Maria Thais Mariani Marco Campione Elena Offidani Annamaria Parodi Aurora Prignano Francesca Australasian Journal of Dermatology AbstractPalmoplantar (PP) psoriasis is considered one of the most hard‐to‐treat areas with important impact on patients' quality of life, and few data are available about the efficacy of dimethylfumarate (DMF) on these areas. In our noninterventional multicentre retrospective cohort study of patients with PP psoriasis treated with DMF, effectiveness was evaluated as mean pp Psoriasis Area and Severity Index (ppPASI) reduction and as proportion of patients that reach ppPASI 75 at 4, 12, 24 and 48 weeks. The reduction in ppPASI was 23.5% at w4, 49.7% at w12, 69.1% at w24 and 81.1% at w48. pp Investigator's Global Assessment (ppIGA) 0/1 was reached by 5 patients (10.64%) at w4, 10 patients (23.8%) at w12, 11 patients (40.7%) at w24 and 12 patients (60%) at w48 confirming that DMF could represent an effective therapy in patients affected by PP psoriasis. Overall, the treatment was well tolerated although only 24 patients made it to 24 weeks of therapy and 28 patients completed the observation period at 48 weeks. None of the patients reported adverse events requiring discontinuation of the drug. However, this discontinuation rate is in line with clinical trials and real‐world evidence. 10.1111/ajd.14213 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Real‐life experience with dimethylfumarate in palmoplantar psoriasis: A multicentre retrospective Italian study |
| topic | Australasian Journal of Dermatology |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ajd.14213 |